Curza Global, LLC and o2h discovery are pleased to announce a multi FTE chemistry collaboration to support Curza as it drives its lead program targeting dram negative through lead optimization and towards the clinic.
Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome.
o2h discovery is pleased to collaborate with industry leader, Curza, to tackle the rapid and global spread of antimicrobial resistance. Working through different pathways Curza hopes to design effective new drugs to tackle gram-negative infections The approach Curza has taken is unique and management is very focused to ensure their drug makes its way to patients quickly.
Sunil Shah, CEO of o2h group “The rapid and global spread of antimicrobial-resistant organisms in recent years has been unprecedented. Although resistant Gram-positive infections have been concerning to clinicians, the increasing incidence of antibiotic-resistant Gram-negative infections have become the most pressing issue in bacterial resistance.”
Ryan Davies, CEO of Curza “We are very happy to be working with o2h discovery on this program. We wanted to make fast progress with this project and o2h discovery’s focus on execution speed is a key reason why we selected them to work on our highest priority project.
About o2h group: o2h group seeds new ideas in science, technology and social enterprise. We work across boundaries and take a collaborative and shared approach to innovation, and therefore we co-invest, co-create and co-execute to bring these ideas to life. o2h discovery is an integrated chemistry and biology services capability for collaborative research and o2h ventures supports early stage life science assets through seed investment. o2h group is organized into 6 verticals including discovery, ventures, technology, therapeutics, co-work and community, and is co-located in Ahmedabad, India and in Cambridge UK. Please see www.o2h.com for more details.
About Curza: Curza is a Utah-based drug development company focused on developing novel therapeutics to control antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and backed by Clarke Capital Partners and other private investors. Please visit www.curza.com for more information.
